Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock Holdings Lifted by SG Americas Securities LLC

SG Americas Securities LLC boosted its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 2,005.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 695,907 shares of the company's stock after acquiring an additional 662,861 shares during the period. SG Americas Securities LLC owned 0.27% of Maravai LifeSciences worth $1,538,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Alyeska Investment Group L.P. boosted its holdings in shares of Maravai LifeSciences by 145.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 5,329,420 shares of the company's stock valued at $29,045,000 after acquiring an additional 3,161,072 shares in the last quarter. Marshall Wace LLP boosted its holdings in Maravai LifeSciences by 17,912.9% in the 4th quarter. Marshall Wace LLP now owns 2,778,497 shares of the company's stock valued at $15,143,000 after purchasing an additional 2,763,072 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in Maravai LifeSciences by 29.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,664,210 shares of the company's stock worth $25,420,000 after purchasing an additional 1,062,485 shares during the period. CenterBook Partners LP acquired a new position in Maravai LifeSciences during the 4th quarter worth approximately $4,425,000. Finally, Pier Capital LLC raised its stake in shares of Maravai LifeSciences by 137.0% during the 4th quarter. Pier Capital LLC now owns 1,127,773 shares of the company's stock worth $6,146,000 after buying an additional 651,921 shares in the last quarter. 50.25% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MRVI has been the subject of a number of recent analyst reports. Craig Hallum reduced their target price on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Stifel Nicolaus set a $5.00 price objective on Maravai LifeSciences in a research note on Friday, March 21st. Morgan Stanley reduced their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating for the company in a report on Tuesday, March 25th. UBS Group lowered their price target on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Finally, Bank of America cut their price objective on Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Maravai LifeSciences has a consensus rating of "Hold" and an average price target of $6.64.

Maravai LifeSciences Trading Up 1.4%

Shares of NASDAQ MRVI traded up $0.03 during midday trading on Monday, hitting $2.16. The stock had a trading volume of 1,009,205 shares, compared to its average volume of 2,329,544. Maravai LifeSciences Holdings, Inc. has a 1-year low of $1.67 and a 1-year high of $10.03. The company has a fifty day moving average price of $2.07 and a 200 day moving average price of $3.50. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $550.07 million, a price-to-earnings ratio of -1.32 and a beta of 0.25.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The firm had revenue of $46.85 million during the quarter, compared to analysts' expectations of $44.01 million. Maravai LifeSciences's quarterly revenue was down 26.9% on a year-over-year basis. On average, analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.24 earnings per share for the current year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.